NO20081482L - Delta- og epsilon-krystallformer for imatinibmesylat - Google Patents

Delta- og epsilon-krystallformer for imatinibmesylat

Info

Publication number
NO20081482L
NO20081482L NO20081482A NO20081482A NO20081482L NO 20081482 L NO20081482 L NO 20081482L NO 20081482 A NO20081482 A NO 20081482A NO 20081482 A NO20081482 A NO 20081482A NO 20081482 L NO20081482 L NO 20081482L
Authority
NO
Norway
Prior art keywords
crystal forms
delta
imatinib mesylate
preparation
pharmaceutical compositions
Prior art date
Application number
NO20081482A
Other languages
English (en)
Inventor
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37192362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081482(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20081482L publication Critical patent/NO20081482L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives d- og e-krystallformer av metansulfonsyreaddisjonssaltet av 4-(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]benzamid (forbindelsen med formel I, se nedenfor). Videre beskrives prosesser for fremstilling derav, farmasøytiske preparater inneholdende disse krystallformer, og deres anvendelse i diagnostiske metoder eller for terapeutisk behandling av varmblodige dyr, samt brukt som mellomprodukter ovenfor fremstilling av farmasøytiske preparater for anvendelse ved diagnostiske metoder eller for terapeutiske behandlinger av varmblodige dyr, særlig mennesker.
NO20081482A 2005-08-26 2008-03-26 Delta- og epsilon-krystallformer for imatinibmesylat NO20081482L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71173805P 2005-08-26 2005-08-26
US71173705P 2005-08-26 2005-08-26
US71220605P 2005-08-29 2005-08-29
PCT/EP2006/065662 WO2007023182A1 (en) 2005-08-26 2006-08-24 Delta and epsilon crystal forms of imatinib mesylate

Publications (1)

Publication Number Publication Date
NO20081482L true NO20081482L (no) 2008-05-16

Family

ID=37192362

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081482A NO20081482L (no) 2005-08-26 2008-03-26 Delta- og epsilon-krystallformer for imatinibmesylat

Country Status (16)

Country Link
US (1) US7879860B2 (no)
EP (1) EP1922314A1 (no)
JP (1) JP2009506014A (no)
KR (1) KR20080049766A (no)
CN (2) CN102002035B (no)
AR (1) AR055613A1 (no)
AU (1) AU2006283842B2 (no)
BR (1) BRPI0615383A2 (no)
CA (1) CA2620835A1 (no)
EC (1) ECSP088217A (no)
IL (1) IL189353A (no)
MX (1) MX2008002541A (no)
MY (1) MY148375A (no)
NO (1) NO20081482L (no)
UY (1) UY29766A1 (no)
WO (1) WO2007023182A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006316823A1 (en) 2005-11-25 2007-05-31 Novartis Ag F,G,H,I and K crystal forms of imatinib mesylate
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
EP1919893A2 (en) 2006-04-27 2008-05-14 Sicor, Inc. Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
EP2009008A1 (en) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
US20090012296A1 (en) * 2007-05-29 2009-01-08 Alexandr Jegorov Processes for the preparation of crystalline form beta of imatinib mesylate
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
US7947699B2 (en) 2008-01-10 2011-05-24 Actavis Group Ptc Ehf Anhydrous amorphous imatinib mesylate
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
AU2011213936A1 (en) 2010-02-15 2012-09-06 Sharma Ashwani Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
CN102477031B (zh) 2010-11-30 2015-07-15 浙江九洲药业股份有限公司 一种甲磺酸伊马替尼α晶型的制备方法
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
EP2864313A1 (en) 2012-06-22 2015-04-29 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
CN103570676B (zh) * 2012-08-04 2016-03-16 正大天晴药业集团股份有限公司 甲磺酸伊马替尼α结晶的制备及其药物组合物
ES2683361T3 (es) 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
WO2017129624A1 (en) 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
PL3539138T3 (pl) 2016-11-11 2021-12-13 Curium Us Llc Sposoby generowania germanu-68 ze zmniejszoną ilością części lotnych
CN112851640B (zh) * 2019-11-28 2023-09-01 广东东阳光药业股份有限公司 嘧啶苯甲酰胺化合物的硫酸盐及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TR200504337T1 (tr) * 2003-06-02 2006-12-21 Hetero Drugs Limited Imatinib mezilat'ın yeni polimorfları
US8048883B2 (en) 2004-02-11 2011-11-01 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
UA84462C2 (ru) * 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate

Also Published As

Publication number Publication date
ECSP088217A (es) 2008-03-26
JP2009506014A (ja) 2009-02-12
CN101243066A (zh) 2008-08-13
CN102002035A (zh) 2011-04-06
US7879860B2 (en) 2011-02-01
EP1922314A1 (en) 2008-05-21
WO2007023182A1 (en) 2007-03-01
UY29766A1 (es) 2007-03-30
AU2006283842A1 (en) 2007-03-01
BRPI0615383A2 (pt) 2011-05-17
AR055613A1 (es) 2007-08-29
CN101243066B (zh) 2012-11-14
IL189353A (en) 2014-12-31
KR20080049766A (ko) 2008-06-04
US20080254116A1 (en) 2008-10-16
CN102002035B (zh) 2013-02-27
CA2620835A1 (en) 2007-03-01
IL189353A0 (en) 2008-06-05
MX2008002541A (es) 2008-03-14
MY148375A (en) 2013-04-15
AU2006283842B2 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
NO20082684L (no) F-, G-, H-, I- og K-krystallformer av imatinibmesylat
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20050828L (no) lndol-3-svovelderivater
NO20055219L (no) Nye forbindelser
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20090628L (no) Pyridizinon derivativater
NO20066055L (no) Pyridinderivater
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20082496L (no) Pyrazinderivater
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20064015L (no) Kondenserte derivater av pyrazol
NO20090328L (no) Nye forbindelser 385
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20064584L (no) Tetrahydropyridoindolderivater
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20081844L (no) Terapeutiske forbindelser
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application